CAS: 5240-72-2; Bicyclo[2.2.1]Heptan-2-Ylmethanol

相似化合物

824-62-4 19396-83-9 13137-31-0

上下游产品

heptylmethyl acetate2-Bicyclo2.2.1heptylmethyl acetate methanol norborn-2-ene Methyl formate 2-iodomethyl-norbornane (3aS,6aS)-1,2,3,3a,4,6a-Hexahydro-pentalene heptylmethyl acetate2-Bicyclo2.2.1heptylmethyl acetate norbornane-2-carboxaldehyde

📜5-降冰片烯-2-甲醇置于氢气体系中,用 乙醇 作为反应溶剂,以100%的收率获得产物2-降莰烷甲醇
参考文献:人本构蛋白酶体β5C选择抑制剂的基于结构的设计.
标题:人本构蛋白酶体β5C选择抑制剂的基于结构的设计.
摘要:这项工作报告了人类组成型蛋白酶体β5C催化活性的高效和选择性抑制剂的发展.该工作描述了设计原理,即大疏水性p3残基和小疏水性p1残基,这些原理导致合成了一组肽环氧基酮;他们的评估和最有希望的化合物的选择,以进行进一步的分析.构效关系详细说明了随着化合物逐步多样化,β1C/ I,β2C/ I和β5I活性如何对抑制产生抗性.以顺式和反式的混合物形式获得了最有效的化合物-双环己基异构体和对映选择性合成解决了这个问题.与某些化合物复合的酵母蛋白酶体结构的研究为效力和特异性提供了理论依据.用最有效的化合物中的n末端替代更易溶的等同物会导致细胞渗透性分子选择性地和有效地阻断表达组成型蛋白酶体和免疫蛋白酶体的细胞中的β5C.
DOI:10.1021/acs.Jmedchem.6B00705

专利信息

专利号:US-2002127598-A1
优先权日:2000-03-27
标题 :Solution-phase combinatorial library synthesis and pharmaceutically active compounds produced thereby
发明人：ZHOU WENQIANG; UPENDRAN SATHYA; IYER RADHAKRISHNAN P
摘要:The invention provides methods for solution-phase synthesis of nucleotide-based compounds and new libraries of such compounds. Compounds of the invention are useful for a variety of therapeutic applications, including treatment of viral or bacterial infections and associated diseases and disorders.

专利号:US-6620796-B1
优先权日:1999-11-08
标题:Combinatorial library synthesis and pharmaceutically active compounds produced thereby
发明人：ZHOU WENQIANG; JIN YI; ROLAND ARLENE; IYER RADHAKRISHNAN
权利人:MICROLOGIX BIOTECH INC
摘要:The invention provides new methods for synthesis of nucleotide-based compounds and new libraries of such compounds. Compounds of the invention are useful for a variety of therapeutic applications, including treatment of viral or bacterial infections and associated diseases and disorders.

专利号:WO-2012163936-A1
优先权日:2011-05-31
标 题 :Process for the synthesis of benzotriazoles useful as uv-filters
发明人：PRESCHEL MICHAEL; ROEDER MICHAEL; SCHLIFKE-POSCHALKO ALEXANDER; ZHANG KESHENG
权利人:DSM IP ASSETS BV; PRESCHEL MICHAEL; ROEDER MICHAEL; SCHLIFKE-POSCHALKO ALEXANDER; ZHANG KESHENG
摘要:The invention relates to an improved process for the manufacture of novel benzotriazoles as well to novel benzotriazoles obtained by the novel process. This novel economical process provides products in high purity and yields.

专利号:WO-2010115869-A1
优先权日:2009-04-03
标 题 :Propofol phosphonyl derivatives, synthesis, and use in long acting formulations
发明人：GONNISSEN YVES RENE JOHANNA PAUL
权利人:SEPS PHARMA N V; GONNISSEN YVES RENE JOHANNA PAUL
摘要:This invention relates to compounds represented by the structural formula (I), and the salts and stereoisomers thereof, wherein: - L is a linker selected from the group consisting of -(CH 2 ) P -O-, a single bond, formula (IA), -(CH 2 ) 1-8 -O-X(O)-, and - p is an integer from 1 to 8, - each R 3 and each R 4 is independently selected from the group consisting of C 1-20 alkyl, C 3-12 alkyl, C 3-12 cycloalkyl-C 1-4 alkyl, saturated heterocyclyl and saturated heterocyclyl-C 1-4 alkyl, and - X and Y are each independently C or S(O), - Z is selected from the group consisting of O, S(O) and NR 5 , - W is selected from the group consisting of halogen, OH, S(O)H and O - M + wherein M + is a monovalent cation; and - R 5 is selected from the group consisting of hydrogen and C 1-10 alkyl. These compounds are useful pharmaceutical agents with improved oral bioavailability.

专利号:WO-2019143423-A1
优先权日:2018-01-17
标题:Flow controlled synthesis of bottlebrush macromolecules

专利号:WO-9855085-A1
优先权日:1997-06-04
标题:Pharmaceutical compositions and methods
发明人：BROWN DAVID A; KHORLIN ALEXANDER A; LESIAK KRYSTYNA; REN WU YUN
权利人:CODON PHARMACEUTICALS INC; BROWN DAVID A; KHORLIN ALEXANDER A; LESIAK KRYSTYNA; REN WU YUN
摘要:Disclosed are methods and compositions for regulating the melanin content of mammalian melanocytes; regulating pigmentation in mammalian skin, hair, wool or fur; treating or preventing various skin and proliferative disorders; increasing the differentiation of mammalian neuronal cells for purposes of treating neurodegenerative diseases or nerve damage; and stimulating cellular nitric oxide (NO) synthesis, cyclic guanosine monophosphate levels (cGMP), and protein kinase G (PKG) activity for purposes of treating diseases mediated by deficiencies in the NO/cGMP/PKG signal transduction pathway; by administration of various compounds, including alcohols, diols and/or triols and their analogues.